Navigation Links
Synapse Biomedical Receives $2.4 Million
Date:12/18/2013

CLEVELAND, Dec. 18, 2013 /PRNewswire-USNewswire/ -- Synapse Biomedical Inc. (www.synapsebiomedical.com) announced today it has been awarded approximately $2.4 million in funding from Ohio Third Frontier Commission to support the next generation design and development of the NeuRx® technology to expand its indications for use in managing critical care patients with respiratory  insufficiency.

(Logo: http://photos.prnewswire.com/prnh/20131218/DC35499LOGO)

(Fact sheets, patient testimonial, product video and images: www.synapsebiomedical.com/news/media)

"This is an important award for Synapse Biomedical which will significantly accelerate timing of our next clinical trial. We anticipate the NeuRx® and Transloc® technology will lead to a reduction in length of stay (LOS) and improved outcomes for critical care patients.  This support from the Ohio Third Frontier Commission is an important third component in our public, academic and private partnership to make these devices available," said Anthony Ignagni, President and Chief Executive Officer. The technology originated at Case Western Reserve University for spinal cord injured patients and was then developed further by Synapse for ALS and now critical patients.

According to US Department of Health and Human Services 2011 report, over 1.6 million people each year are intubated with mechanical ventilation which results in more than 110,000 people requiring invasive tracheostomy and extended ventilator support.

"Up to 20% of patients who receive mechanical ventilation in the Surgical Intensive Care Unit (SICU) can have difficulty weaning from a ventilator, so the impact of the results of this clinical trial will be significant.  The cumulative effect of mechanical ventilation and the link to ventilator acquired pneumonia are well documented," said Dr. Raymond Onders, co-founder of Synapse Biomedical and Margaret and Walter Remen Chair in Surgical Innovation at University Hospitals Case Medical Center.

A positive end result of the trial will impact intensive care unit management of mechanical ventilation at Acute Care Hospitals.  The NeuRx® technology should lead to a reduction in the cost of care of these ventilated patients as they are the leading costs in the U.S. Healthcare system at $81 billion, according to the Department of Health and Human Services 2011 report.

"In our clinical trial we will collaborate with thought-leading surgeons and critical care physicians in major academic research institutions (www.synapsebiomedical.com/als/usneurx-centers.shtml).   It's very exciting news for our existing customers who have been requesting access to this application for years," said Steven Annunziato SVP Marketing and Sales.

About NeuRx® Technology
NeuRx Diaphragm Pacing System® (DPS) is a four-channel, battery-powered neurostimulator with implanted electrodes. The device provides electrical stimulation to the muscle and nerves of the diaphragm. 

The NeuRx DPS® received CE Marking (CE Registration #518356) on November 20, 2007 and is approved for treating patients with diaphragm dysfunction in the European Union.

The NeuRx DPS® received FDA approval for ventilator dependency from spinal cord injury on June 17, 2008. In Spinal Cord Injury (SCI), the NeuRx DPS® provides ventilatory support in patients with diaphragm dysfunction of neuromuscular origin.  Diaphragm dysfunction can result in abnormal or absent respiration in patient populations of high-level spinal cord injury and other injuries or diseases affecting the neuromuscular respiratory pathways. 

The NeuRx DPS® received FDA approval for treating chronic hypoventilation from ALS on September 28, 2011. The NeuRx DPS® has demonstrated that it can help people with ALS live longer and sleep better than the current standard of care, alone. 

For more information on current indications for use, please visit
www.synapsebiomedical.com/products/patientInfo.shtml  

About Synapse Biomedical
Founded in 2002, Synapse Biomedical's mission is to commercialize our life transforming neurostimulation platform used to treat people with respiratory insufficiency. Synapse is based in Oberlin, Ohio, approximately 30 miles west of Cleveland.  For more information, including fact sheets, frequently asked questions, high resolution images and broadcast quality video, please visit www.synapsebiomedical.com/news/media.

About OHIO Commercial Acceleration Loan Fund
The Commercial Acceleration Loan Fund (CALF) is an Ohio Third Frontier program providing early-stage funding to investment-validated Ohio companies to develop next generation products and services. The program seeks to support companies and technology platforms that represent a potential path to growth, market entry and/or entering the regulatory approval process within three to five years.


'/>"/>
SOURCE Synapse Biomedical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FUJIFILM Synapse® Mobility 3.0 Now Available In The U.S.
2. BHR Pharma Expands SyNAPSe® Trial into Thailand, China and Russia
3. Synapse Develops Technology for Innovative Asthma Management Device
4. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
5. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
6. Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester
7. Fluke Biomedical device first to achieve environmentally-friendly label
8. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
9. The Biomedical Device Industry in America: Challenges at Home and Abroad
10. Carnegie Mellon University Biomedical Engineers Lead Collaborative Team Developing New Astro Surgery Tools for NASA Deep Space Missions
11. KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):